Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF

M Colleoni*,1, HJ Litman2, M Castiglione-Gertsch3, W Sauerbrei4, RD Gelber1, M Bonetti3, AS Coates5, M Schumacher6, G Bastert7, C-M Rudenstam8, C Schmoor 4, J Lindtner 9, J Collins10, B Thürlimann11, SB Holmberg8, D Crivellari12, C Beyerle13, RLA Neumann 6 and A Goldhirsch1,14 for the International Breast Cancer Study Group and the German Breast Cancer Study Group

1European Institute of Oncology, Milan, Italy; 2IBCSG Statistical Center, Dana-Farber Cancer Institute and Frontier Science and Technology Research Foundation, Boston, Massachusetts, USA; 3IBCSG Coordination Center, Bern, Switzerland; 4Institute of Medical Biometry and Medical Informatics, University Hospital of Freiburg, Freiburg, Germany; 5The Cancer Council Australia and University of Sydney, Sydney, Australia; 6Department of Gynaecology, Marien Hospital Essen-Altenessen, Essen, Germany; 7Department of Gynaecology, University Hospital of Heidelberg, Heidelberg, Germany; 8Western Sweden Breast Cancer Study Group, Sahlgrenska University Hospital, Göteborg, Sweden; 9Institute of Oncology, Ljubljana, Slovenia; 10Anti-Cancer Council of Victoria, Melbourne, Australia; 11Kantonsspital, St. Gallen, Switzerland; 12Centro di Riferimento Oncologico, Aviano, Italy; 13Department of Gynaecology, Kreiskrankenhaus Kronach, Kronach, Germany; 14Oncology Institute of Southern Switzerland, Lugano, Switzerland

Cyclophosphamide, methotrexate and fluorouracil adjuvant combination chemotherapy for breast cancer is currently used for the duration of six monthly courses. We performed a joint analysis of two studies on the duration of adjuvant cyclophosphamide, methotrexate and fluorouracil in patients with node-positive breast cancer to investigate whether three courses of cyclophosphamide, methotrexate and fluorouracil might suffice. The International Breast Cancer Study Group Trial VI randomly assigned 735 pre- and perimenopausal patients to receive ‘classical’ cyclophosphamide, methotrexate and fluorouracil for three consecutive cycles, or the same chemotherapy for six consecutive cycles. The German Breast Cancer Study Group randomised 289 patients to receive either three or six cycles of i.v. cyclophosphamide, methotrexate and fluorouracil day 1, 8. Treatment effects were estimated using Cox regression analysis stratified by clinical trial without further adjustment for covariates. The 5-year disease-free survival per cents (± s.e.) were 54 ± 2% for three cycles and 55 ± 2% for six cycles (n=1024; risk ratio (risk ratio: CMF x 3/CMF x 6), 1.00, 95% confidence interval, 0.85 to 1.18; P=0.99). Use of three rather than six cycles was demonstrated to be adequate in both studies for patients at least 40-years-old with oestrogen-receptor-positive tumours (n=594; risk ratio, 0.86; 95% confidence interval, 0.68 to 1.08; P=0.19). In fact, results slightly favoured three cycles over six for this subgroup, and the 95% confidence interval excluded an adverse effect of more than 2% with respect to absolute 5-year survival. In contrast, three cycles appeared to be possibly inferior to six cycles for women less than 40-years-old (n=190; risk ratio, 1.25; 95% confidence interval, 0.87 to 1.80; P=0.22) and for women with oestrogen-receptor-negative tumours (n=302; risk ratio, 1.15; 95% confidence interval, 0.85 to 1.57; P=0.37). Thus, three initial cycles of adjuvant cyclophosphamide, methotrexate and fluorouracil chemotherapy were as effective as six cycles for older patients (40-years-old) with oestrogen-receptor-positive tumours, while six cycles of adjuvant cyclophosphamide, methotrexate and fluorouracil might still be required for other cohorts. Because endocrine therapy with tamoxifen and GnRH analogues is now available for younger women with oestrogen-receptor-positive tumours, the need for six cycles of cyclophosphamide, methotrexate and fluorouracil chemotherapy is unclear and requires further investigation.

British Journal of Cancer (2002) 86, 1705 – 1714. doi: 10.1038/sj.bjc.6600334 www.bjcancer.com
© 2002 Cancer Research UK

Keywords: breast cancer; chemotherapy duration; cyclophosphamide, methotrexate and fluorouracil (CMF); predictive factors

The question of duration of adjuvant chemotherapy for breast cancer has been directly addressed in several trials. Most of these were small and, therefore, unsuitable for detecting differences of modest magnitude (Bonadonna et al, 1987; Levine et al, 1990; Senn and Jungi, 1984; Falkson et al, 1989; Henderson et al, 1986). A meta-analysis of six such trials showed that a shorter treatment duration (6 months) was as effective as a longer duration therapy (12–24 months) (Early Breast Cancer Trialists’ Collaborative Group, 1998a). The International Breast Cancer Study Group (IBCSG) Trial V investigated the role of a single cycle of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) immediately after the operation as compared with six or seven cycles of the...
same treatment for patients with node-positive disease (Ludwig Breast Cancer Study Group, 1988). Although a single cycle of perioperative chemotherapy improved outcome compared with no adjuvant chemotherapy in node-negative disease (Ludwig Breast Cancer Study Group, 1989), such treatment was found to be less effective than a longer duration CMF in node positive disease (Ludwig Breast Cancer Study Group, 1988). Without considering subgroups, these results suggest that the optimal duration of adjuvant CMF therapy for breast cancer is more than one but not more than six 28-day cycles. The duration of a typical anthracycline-containing regimen tested in several adjuvant trials is 3 months (administered once every 3 weeks for four courses). This regimen yielded similar disease-free and overall survival results compared with six courses of CMF (Fisher et al, 1990, 2000).

Recently, the German Breast Cancer Study Group (GBSG) reported the 10-year follow-up results of a randomised trial in 481 node-negative patients comparing three versus six cycles of day 1 and 8 i.v. CMF (modified Bonadonna regimen) with or without tamoxifen (Sauerbrei et al, 2000). No difference in overall survival or event-free survival between the two durations of CMF was found. The International Breast Cancer Study Group (IBCSG) Trial VI compared three versus six cycles of initial ‘classical’ CMF (oral cyclophosphamide) with or without three additional single cycles of ‘reintroduction’ CMF for 1554 premenopausal women with node-positive breast cancer. At 5 years’ median follow-up, the IBCSG previously reported that three cycles of adjuvant CMF chemotherapy yielded a shorter disease-free survival compared with longer duration treatment, based on the entire trial population (International Breast Cancer Study Group, 1996).

However, the increased risk of relapse with CMF × 3 was marked for women aged less than 40 years and for patients with ER-negative tumours (International Breast Cancer Study Group, 1996); patients older than 40 years had similar disease-free survival times. Furthermore, the patients assigned to three cycles showed more rapid adjustment in self-reported quality of life (Hürny et al, 1996) and had significantly less objective and subjective toxicity than those assigned longer duration of therapy (International Breast Cancer Study Group, 1996). To further clarify the role of duration of adjuvant chemotherapy, we report a joint analysis using individual data based on the recently published results of the GBG trial and updated results of IBCSG Trial VI with a median follow-up of 7.9 years. Both studies included two additional arms (two by two designs) that are not the subject of this report.

PATIENTS AND METHODS
Description of trials
From July 1986 to April 1993, 1554 pre- and perimenopausal breast cancer patients with node-positive disease were randomised in IBCSG Trial VI in a two by two factorial design to receive the following: (A) cyclophosphamide, methotrexate, and fluorouracil for six consecutive cycles on months 1 to 6 (CMF × 6); (B) CMF × 6 plus three single cycles of reintroduction CMF given on months 9, 12 and 15; (C) CMF for three consecutive cycles on months 1 to 3 (CMF × 3); or (D) CMF × 3 plus three single cycles of reintroduction CMF given on months 6, 9 and 12. The randomisation was stratified according to the type of surgery (mastectomy vs breast-conserving procedure with breast irradiation), and oestrogen receptor (ER) status (negative vs positive). The median follow-up was 7.8 years for disease-free survival and 7.9 years for overall survival. The protocol required that the adjuvant chemotherapy begin within 6 weeks of surgery and consist of CMF (cyclophosphamide 100 mg m⁻² orally days 1-14, methotrexate 40 mg m⁻² i.v. days 1 and 8, 5-fluorouracil 600 mg m⁻² i.v. days 1 and 8, repeated every 28 days). Oestrogen receptor concentrations in the primary tumours were determined by standard methods and concentrations ≥10 fmol mg⁻¹ of cytosol protein were considered positive; lower values negative. Surgery of the primary tumour was either a total mastectomy with axillary clearance, or a lesser procedure (quadrantectomy or lumpectomy) with axillary lymph node dissection. For women treated with breast conserving surgery, radiotherapy was mandatory and had to be postponed until the end of the initial phase of chemotherapy (3 or 6 cycles).

From 1984 to 1989, 481 breast cancer patients were randomised in the GBSG Trial in a two by two factorial design to receive either three or six cycles of CMF and to receive two years of hormonal therapy with tamoxifen or no hormonal therapy. The trial design was the following: (A) CMF × 3; (B) CMF × 3+tamoxifen; (C) CMF × 6; and (D) CMF × 6+tamoxifen. At the beginning of the study, both pre- and postmenopausal patients were randomised to all four arms of the study. However, starting in December 1986, premenopausal patients were only randomised to treatment arms A and C. Chemotherapy was administered according to the modified Bonadonna CMF regimen, which consisted of 500 mg m⁻² cyclophosphamide, 40 mg m⁻² methotrexate, and 600 mg m⁻² fluorouracil administered intravenously on days 1 and 8 of a 4-week treatment period. Chemotherapy started within 36 h after surgery. Hormonal treatment consisted of a daily dose of 3 x 10 mg tamoxifen orally over 2 years, starting after the third cycle of CMF. The median follow-up was 9.1 years for disease-free survival and 10.0 years for overall survival.

Statistical methods
A joint analysis of the two studies was performed to compare the effectiveness of CMF × 3 and CMF × 6. Only data from arms A and C from both studies were used in the analysis (CMF × 3 only and CMF × 6 only treatment arms: Seven hundred and thirty-five patients from the IBCSG trial and 289 patients from the GBSG trial). Patient characteristics according to randomised treatment are presented for each of the trials in Table 1. Disease-free survival (DFS) was defined as the time from surgery to relapse, second malignancy, or death without relapse, whichever occurred first. Overall survival (OS) was defined as the time from surgery to death from any cause. Five-year DFS rates were calculated for each treatment group by trial, as well as by age group (<40, ≥40), by ER status (negative, positive), and, for the IBCSG trial only, by both age group and ER status. Risk ratios (RR) with pointwise confidence intervals for DFS comparing CMF × 3 to CMF × 6 were calculated based on Cox models stratified by clinical trial without inclusion of covariates (Cox, 1972). An RR greater than one demonstrated that the risk of disease relapse for patients treated with CMF × 3 was higher than for patients treated with CMF × 6. Chi-square Wald statistics for the null hypothesis that the RR equals one were calculated. Two-sided P-values less than 0.05 from this test were considered significant. Nine cases in the GBSG trial did not have ER values, so they are not included in the DFS risk ratios by ER status.

A graph of 95% confidence intervals (CI) for the RR overall and by age and ER status is presented in Figure 1. The size of the boxes on the figure represents the amount of information available from each subset (the larger the box, the more information provided). Specifically, the box size is inversely proportional to the standard error of the estimate of the natural log of the RR. Kaplan–Meier curves of DFS for the two trials by treatment arm and also by age group were generated (Kaplan and Meier, 1958). Kaplan–Meier curves of OS by cooperative group and treatment arm were created. To describe the relationship between age and the magnitude of treatment difference we used subpopulation treatment effect pattern plots (STEPPs). This statistical method provides estimates of the hazards ratios computed by the Cox model fitted on overlapping subpopulations of patients, where the subpopulations are
defined so that they contain patients having increasing age (Bonetti and Gelber, 2000). A second implementation of STEPP describes the 3-year DFS estimated for each treatment group within each of the overlapping subpopulations (Bonetti and Gelber, 2001).

Differences between the two CMF 3 vs 6 trials

The administration of CMF regimens differed between the trials. Patients in the GBSG trial received i.v. CMF (modified Bonadonna regimen), while oral cyclophosphamide and i.v. methotrexate and fluorouracil were given to patients in the IBCSG trial.

Patients in the GBSG study were randomised in most cases following three cycles of CMF to avoid including early drop-outs in the data analysis. Patients in the IBCSG study were randomised prior to the first cycle of CMF. To maintain consistency between the two trials, surgery date was used as a common starting date for calculation of time to event endpoints (age, DFS, and OS). In the IBCSG study, follow-up information for DFS and for OS were obtained from study forms submitted to the data management center. In the GBSG study, DFS and OS were based on clinic data; however, for some patients or clinics, contacts were lost after some time. In these cases, information about survival status was requested from the corresponding registration office. This additional information was used for OS only.

In the published report on the GBSG study, patients with ER values of 20 fmol mg\(^{-1}\) or greater were considered ER-positive. ER values of 10 fmol mg\(^{-1}\) or greater were ER-positive in the IBCSG study. The joint analysis considered ER values of 10 fmol mg\(^{-1}\) or greater to be ER-positive.

Timing of scheduled follow-up visits differed between the two trials. In the IBCSG trial, the patients were seen every 3 months for the first 2 years, every 6 months for the next 3 years, and then annually thereafter. Patients were scheduled to be seen more frequently in the GBSG trial. They were seen every 3 months for the first 2 years after the operation, every 4 months for the following 3 years, every 6 months for the following 2 years, and then annually thereafter. Median follow-up was 7.8 years for disease free survival in the IBCSG trial and 9.1 years in the GBSG trial. Of the 735 IBCSG patients, 381 had an event and of the 289 GBSG patients, 170 had an event. Median overall follow-up for the IBCSG study was 7.8 years and 10.0 years for the GBSG trial. 254 of the 735 IBCSG patients died, and 143 of the 289 GBSG patients died thus far.

As shown in Table 1, 51% of patients in the GBSG trial were at least 50 years of age, while only 18% of patients in the IBCSG trial were 50 or older. The majority of patients in both the GBSG and IBCSG trials had ER-positive tumours (69 and 70%, respectively). Most patients in both trials had between one and three positive nodes (59 and 65%, respectively). A higher percentage of patients in the GBSG trial had tumours larger than two centimeters, 71% compared with 55% in the IBCSG trial. All of the GBSG patients and 71% of the IBCSG patients had mastectomies.

RESULTS

Across all patients from both trials, DFS RRs of CMF × 3 versus CMF × 6 revealed no difference between treatment groups (Figure 1, top). The RR for the 1024 patients was 1.00, with a DFS Cox model \(P\)-value of 0.99 indicating no DFS difference between the two treatments. Graphically, Figure 2A shows the similar Kaplan–Meier DFS curves for the two treatments within each of the individual trials. The 5-year DFS per cents ± s.e. across both trials were 54 % ± 2% for three cycles and 55% ± 2% for six cycles (absolute difference [95% CI], −1% [−7% to +6%]). The RR of OS for the 1024 patients was 1.10 with 95% CI 0.90 to 1.34 (\(P=0.35\)). Figure 2B shows Kaplan–Meier curves for OS. The five-year OS per cents ± s.e. across both trials were 74% ± 2% for three cycles and 76% ± 2% for six cycles (absolute difference [95% CI], −1% [−7% to +4%]).

For patients who were less than 40 years old (regardless of ER status), results suggested an increased risk of relapse for patients on CMF × 3 versus CMF × 6. Across both trials, for patients younger than 40 years of age the RR was 1.25 with 95% CI 0.87 to 1.80 (\(P=0.22\); Figure 1). For these patients, the 3-year DFS was 41 ± 5% for CMF × 3 compared with 48 ± 5% for CMF × 6 (Figure 3A). Five-year OS was 66 ± 5% for CMF × 3 compared with 70 ± 5% for CMF × 6 for patients younger than 40 years of age. The STEPP analyses for the IBCSG trial (Figures 4A,C) graphically showed that differences in treatment effect are likely to occur across the continuum of age, with CMF × 3 compromising DFS for patients < 40 compared with CMF × 6. Both the Cox model implementation of STEPP (Figure 4A) and the plot showing 5-year DFS per cents (Figure 4C) illustrate improved outcome for younger patients in the CMF × 6

Table 1 Patient characteristics according to randomised treatment

| Factor            | IBCSG                  | GBSG                  |
|-------------------|------------------------|-----------------------|
|                   | CMF × 3 | CMF × 6 | Both | CMF × 3 | CMF × 6 | Both |
| Total Patients    | 360     | 375    | 735  | 145     | 144     | 289  |
| Age <40           | 23      | 19     | 21   | 14      | 12      | 13   |
| 40–49             | 61      | 61     | 61   | 37      | 36      | 36   |
| 50 or older       | 16      | 20     | 18   | 50      | 52      | 51   |
| ER status         |          |        |      |          |         |      |
| Negative          | 30      | 30     | 30   | 30      | 26      | 28   |
| Positive          | 70      | 70     | 70   | 66      | 72      | 69   |
| Unknown           | 0       | 0      | 0    | 4       | 2       | 3    |
| Nodes positive    |          |        |      |          |         |      |
| Between 1 and 3   | 65      | 65     | 65   | 59      | 60      | 59   |
| Four or more      | 35      | 35     | 35   | 39      | 40      | 40   |
| Unknown           | 0       | 0      | 0    | 2       | 0       | 1    |
| Tumour size       |          |        |      |          |         |      |
| <2 cm             | 43      | 42     | 43   | 28      | 29      | 29   |
| ≥2 cm             | 55      | 55     | 55   | 70      | 71      | 71   |
| Unknown           | 2       | 3      | 2    | 1       | 0       | 0    |
group. Because there were so few patients under 40 in the GBSG trial, this effect could not be investigated in Figures 4B and 4D.

The results for all patients with ER-negative tumours (n=302) also showed a possible increased risk for the CMF $6_{3}$ group (Figure 1, RR=1.15; 95% CI=0.85 to 1.57; P-value=0.37). Five-year DFS Kaplan – Meier estimates for this patient subpopulation were 48±4% for three cycles compared with 54±4% for six cycles of CMF. Five-year OS Kaplan – Meier estimates were 60±4% for three cycles compared with 71±4% for six cycles of CMF. Both the IBCSG and GBSG studies showed that CMF $6_{3}$ may not be sufficient for ER-negative patients (RR 1.18 and 1.08, respectively, Figure 1), although the results were not statistically significant.

The increased risk of relapse in the CMF $6_{3}$ group for patients under 40-years-old was observed both for patients with ER-positive and for those with ER-negative tumours. The RR for patients less than 40-years-old with ER-negative tumours was 1.57 and for patients less than 40 with ER-positive tumours was 1.54. Neither RR was statistically significantly different from one. Because there were so few GBSG patients who were younger than 40, only IBCSG data were used for these calculations (Figure 5).

For patients at least 40-years-old with ER-positive tumours, use of three cycles did not increase the risk of relapse compared with six cycles of CMF (Figure 5, n=594, RR=0.86, 95% CI=0.68 to 1.08, P-value=0.19). This result was consistent for each of the trials. The IBCSG trial had an RR of 0.85 with 95% CI 0.65 to 1.13 and the GBSG trial had an RR of 0.87 with 95% CI 0.59 to 1.28. Across both trials, the 5-year DFS±SE was 61±3% for three cycles of CMF and 57±3% for six cycles of CMF (absolute difference [95% CI], +4% [-4 to +12%]). Five-year OS±SE was 83±2% for three cycles of CMF and 79±2% for six cycles of CMF for patients at least 40 years old with ER-positive tumours (absolute difference [95% CI], +4% [-2 to +11%]).

In general, formal tests for interaction between the duration of CMF and either age or ER status alone were not statistically significant (Figure 1; P-value for age and P-value for ER). Among patients with ER-positive tumours, however, the longer duration treatment provided benefit for younger women but not for older women (Figure 5; P-value for interaction=0.03).

### DISCUSSION

There is high quality evidence that adjuvant cytotoxic chemotherapy delays relapse and prolongs survival for patients with early breast cancer (Early Breast Cancer Trialists’ Collaborative Group, 1998a). As in other areas of medicine, once primary efficacy has been demonstrated research efforts move to evaluate secondary questions addressing optimization of the balance between the benefits of such treatment and its subjective and objective costs. One
such question concerns the optimal duration of adjuvant chemotherapy. In premenopausal women, cytotoxic therapy is thought to exert its effects both by direct tumour cell kill and by an endocrine mechanism secondary to suppression of ovarian function (Pagani et al., 1998). The extent to which chemotherapy may exert such an endocrine effect will depend on the type of chemotherapy, the age of the patient (known to influence the probability of chemotherapy-induced amenorrhea; Pagani et al., 1998; Goldhirsch et al., 1990), and the hormone receptor expression of the tumour (endocrine therapy will be more important in receptor-positive disease; Scottish Cancer Trials Breast Group and ICRF Breast Unit, 1993). Effective alternative forms of endocrine therapy such as tamoxifen (Early Breast Cancer Trialists’ Collaborative Group, 1998b), ovarian ablation, and medical suppression of ovarian function are available, so the optimal duration of cytotoxic therapy may also depend on whether or not such treatments are used. Endocrine non-responsive disease is controlled only by the direct cytotoxic effects of chemotherapy and the benefit of longer duration chemotherapy might best be studied in this setting in the absence of endocrine therapies.

Several trials examine regimens which differ in duration of therapy but also in the drugs given. In these trials the effects of duration and choice of drug are inextricably confounded. They reach varying conclusions about treatment duration. Thus, one of

Figure 2  Kaplan–Meier plots of disease-free survival according to cooperative group and treatment (A) and Kaplan–Meier plots of overall survival according to cooperative group and treatment (B).
the most frequently used anthracycline-containing adjuvant therapy programs, four cycles of intravenous doxorubicin (Adriamycin®) and cyclophosphamide (AC) combination given once every 3 weeks, is administered entirely within 63 days. In a direct comparison, six courses of classical CMF (154 days) and four courses of AC yielded similar results despite the different durations (Fisher et al., 1990, 2000). Likewise a short but complex 16-week regimen (including a continuous administration of cytotoxics during the entire period of treatment) yielded results marginally superior to those seen with six courses of cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) (Fetting et al., 1998). On the other hand, the US Intergroup trial of the addition of 4 cycles of paclitaxel (Taxol®) following four cycles of AC demonstrated a small but significant improvement in disease-free and overall survival using the longer, different regimen (Henderson et al., 1998). This improvement was seen almost exclusively among patients with ER-negative tumours who did not receive tamoxifen.

Evidence already available defines broad limits within which the optimal duration of adjuvant CMF therapy may be expected to be found. The EBCTCG overview found no advantage in extending therapy beyond about 6 months (Early Breast Cancer Trialists’ Collaborative Group, 1998a). International Breast Cancer Study Group Trial V demonstrated that a single peri-operative cycle of CMF was less effective than a course of six or seven cycles of CMF (Ludwig...
Breast Cancer Study Group, 1988) though a single cycle did afford some therapeutic benefit (Ludwig Breast Cancer Study Group, 1989). There is little evidence directly comparing treatment regimens of between more than one and 6 months duration.

There are additional reasons to investigate the question of treatment duration. Subjectively, a course of three cycles of CMF was better tolerated, and associated with more rapid improvement in quality of life than 6 cycles (Hüny et al., 1996). Less toxicity was observed with three cycles of CMF in the GBSG study (Schumacher et al., 1994). Three cycles of CMF chemotherapy was also shown to be effective in addition to tamoxifen therapy in postmenopausal patients, with minimal adverse effect on quality of life (Castiglione-Gertsch et al., 2000). Finally, shorter duration treatments are less costly than longer durations of the same agents.

In this joint analysis we investigated the issue of duration of CMF chemotherapy by choosing two trials, conducted by the IBCSG (International Breast Cancer Study Group, 1996) and the GBSG (Sauerbrei et al., 2000) that used the same three agents in similar schedules and common study questions, though with different routes of cyclophosphamide administration. Both studies also addressed other questions. In this analysis we avoided these potential confounding treatment factors, which included the use of tamoxifen (GBSG) and additional cycles of chemotherapy (IBCSG), by selecting only the data from patients randomised to receive three or six cycles of CMF in each study.

The two studies jointly reviewed here demonstrate that for the overall population and especially for older patients (40 years and above) with hormone-receptor positive tumours three cycles of CMF chemotherapy is nearly identical to six cycles, even in the absence of specific additional endocrine therapy. This is consistent with the EBCTCG overview (Early Breast Cancer Trialists’ Collaborative Group, 1998a), which found a real but relatively small benefit for any chemotherapy in older patients with ER-positive tumours. Such patients are now routinely treated with tamoxifen or ovarian ablation in addition to chemotherapy, presumably further reducing the need for more prolonged cytotoxic therapy. The evidence to support the shorter duration of chemotherapy compared with the longer standard duration is, however, unreliable for younger patients and for those with ER-negative disease, and the longer duration treatment might be beneficial for these cohorts.

Since the current analysis was performed, Maass (2000) have presented preliminary data from a further German trial (GABG III) comparing three versus six cycles of adjuvant CMF and confirming no overall difference between the treatment groups. Based on 789 patients with one to nine axillary lymph nodes involved at a median follow-up of 35 months, no difference in disease-free (P=0.34) or overall survival (P=0.17) was found (three versus six cycles: percent relapsing, 31.3 vs 30.4%; per cent dead, 14.8 vs 12.8%). Data for subgroups according to age and steroid hormone receptor status of the primary tumour were not available.
presented, but no significant treatment difference was found for any subgroup. As far as we know, the GBSG, IBCSG and GABG trials are the only randomised studies evaluating three versus six cycles of CMF, and all demonstrated no overall difference between treatment arms.

We previously published data from IBCSG Trial VI according to amenorrhea suggesting that the endocrine effects of chemotherapy alone are insufficient for the younger age group with ER/PgR positive tumours (Pagani et al., 1998). In this study women who experienced amenorrhea had a significantly better DFS than those who did not. DFS differences between amenorrhea categories were larger for patients with ER/PgR positive tumours. The role of chemotherapy induced amenorrhea appeared evident also when outcome was analyzed in a population of 314 very young (535 years) premenopausal patients enrolled in trials of adjuvant chemotherapy (Aebi et al., 2000). The worst prognosis was observed for younger patients with ER-positive tumours who did not achieve amenorrhea. As indicated by the STEPP plots for the current joint analysis, differences in treatment effect are likely to occur across the continuum of age. Thus, clinical decisions concerning the use of three rather than six courses of CMF might be based on assessment of likelihood for chemotherapy-induced amenorrhea rather than on a fixed age cut-point.

The results of subgroup analyses should be treated with caution, especially because some of the subgroups had small sample sizes. However, there is some biological rationale for expecting benefit of longer duration therapy in the subgroup of patients with ER-negative tumours. Such tumours have a more rapid cell proliferation and are associated with a higher risk of relapse despite adjuvant chemotherapy. Prolonged duration of chemotherapy may, therefore, be particularly relevant to inhibit the growth of tumours that are not susceptible to the effects of endocrine therapies due to lack of ER.

As the risk of relapse increases (higher number of positive nodes) the likelihood that an ER-positive phenotype has a proportion of chemotherapy responsive cells also increases. Therefore, although the overall cohort of older patients with ER-positive tumours was safely treated with the shorter duration of chemotherapy, it is possible that the longer duration of chemotherapy provides a modest benefit for patients with ER-positive tumours at high risk of relapse especially in the absence of tamoxifen (Henderson et al., 1998; Goldhirsch et al., 2000).

Historically, patients were classified as having ER-negative (<10 fmol mg⁻¹ cytosol protein or <10% of positive cells) and ER-positive (≥10 fmol mg⁻¹ cytosol protein or ≥10% of positive cells) tumours to facilitate prediction of response to endocrine therapies. However, there is recent evidence that tumours with less than 10% of weakly positive cells still may experience tumour response, compared with those who had no detectable ER staining (Harvey et al., 1999). These data lead to the conclusion that duration of chemotherapy might be tested best in patients with ER-absent tumours, where the cytotoxic rather than endocrine effects of chemotherapy might be even larger. Although this is a small subset compared with the entire breast cancer population, it might

### Disease-free survival risk ratios

| Group | No. of events/No. of patients | CMFx3 | CMFx6 | RR       | 95% CI   | P-value | 95% CI   |
|-------|-----------------------------|-------|-------|----------|----------|---------|----------|
|       |                             | CMFx3:CMFx6 |       |          |          |         |          |
| <40 ER– | IBCSG                       | 20/31 | 11/23 | 1.57     | (0.75,3.29) | 0.23    |          |
| <40 ER+ | IBCSG                       | 38/52 | 27/47 | 1.54     | (0.94,2.53) | 0.09    |          |
| 40+ ER– | IBCSG                       | 39/78 | 45/88 | 1.04     | (0.68,1.60) | 0.86    |          |
|        | GBSG                        | 24/34 | 17/33 | 1.40     | (0.75,2.63) | 0.29    |          |
| Both   | IBCSG                       | 63/112| 62/121| 1.14     | (0.81,1.63) | 0.45    |          |
| 40+ ER+ | IBCSG                       | 89/199| 112/217| 0.85    | (0.65,1.13) | 0.27    |          |
|        | GBSG                        | 49/87 | 52/91 | 0.87     | (0.59,1.28) | 0.48    |          |
| Both   | IBCSG                       | 138/286| 164/308| 0.86    | (0.68,1.08) | 0.19    |          |

Figure 5 Risk ratios comparing three cycles vs six cycles of CMF according to subpopulations defined by both age (<40, ≥40) and ER status (negative, positive). Because there were so few GBSG patients who were younger than 40, only IBCSG data were used for these calculations.
represent a group particularly relevant for tailored treatment investigations of adjuvant chemotherapy questions, especially in the absence of confounding endocrine therapies.

We conclude that patients with potentially endocrine responsive node-positive disease who are over 40 years of age can be adequately treated with three rather than six cycles of CMF especially if it is followed by tamoxifen. The reduction in the amount of chemotherapy would significantly reduce subjective and objective toxicity. It is difficult to draw firm conclusions for younger patients based on this analysis because there are so few younger patients, particularly in the GBSG trial, and chemotherapy was the only adjuvant treatment. Perhaps three cycles of CMF would be sufficient also for women aged under 40 with hormone receptor positive, potentially endocrine responsive node-negative disease if CMF were followed by effective endocrine therapy. Indeed recent studies (Jakesz et al., 1999; Roche et al., 2000; Boccardo et al., 2000) show endocrine therapy alone with the combination of GnRH analogue plus tamoxifen is equally effective or superior to chemotherapy alone, clearly implying that the endocrine component of any chemoendocrine therapy provides the dominant effect for these patients.

For women of any age with tumours that do not express any steroid hormone receptors (ER-absent) (a relatively small subgroup of patients), the issue of adjuvant chemotherapy duration requires further study, but our results do not suggest that adjuvant CMF can safely be reduced to three cycles in these women.

ACKNOWLEDGEMENTS

We thank the patients, physicians, nurses, and data managers who participate in the International Breast Cancer Study Group (IBCSG) and the German Breast Cancer Study Group (GBSD) trials. We acknowledge the initial support provided for the IBCSG by the Ludwig Institute for Cancer Research, the Cancer League of Ticino, and the Swiss Cancer League. We further acknowledge the continuing support for IBCSG central coordination, data management, and statistics provided by the Swedish Cancer Society, The Cancer Council Australia, Australian New Zealand Breast Cancer Trials Group (NHRCC 880513 and 910420), Frontier Science and Technology Research Foundation, Swiss Group for Clinical Cancer Research, United States National Cancer Institute (CA-75362), and American-Italian Cancer Foundation (AICF 101-98 and 101-99). We acknowledge support for the Cape Town participants from the Cancer Association of South Africa. The GBSG support from the German Bundesministerium für Forschung und Technologie and from the German Research Foundation is gratefully acknowledged.

REFERENCES

Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thurlimann B, Rudenstam CM, Lindner J, Critelli D, Cortes-Funes H, Simioncini E, Werner ID, Coates AS, Goldhirsch A (2000) for the International Breast Cancer Study Group (IBCSG) Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 355: 1869 – 1874

Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Sismondi P, Giai F, Genta F, Pacini P, Distante V, Bolognesi A, Aldrighetti D, Farris A (2000) Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group O2 Randomized Trial. J Clin Oncol 18: 2718 – 2727

Bonadonna G, Valaguapa P, Zambetti M, Buzzoni R (1987) Milan adjuvant trials for stage I-II breast cancer. In Adv and ther treatment covariate interactions in clinical trials. Dana-Farber Cancer Institute Department of Biostatistical Sciences Technical Report Number 583Z.

Castiglione-Gertsch M, Price KN, Nasi ML, Lindner J, Erzen D, Critelli D, Veronesi A, Fey M, Pagani O, Collins J, Forbes J, Rudenstam C-M (2000) Is the addition of adjuvant chemotherapy always necessary in node-negative (N-) postmenopausal breast cancer patients who receive tamoxifen?: first results of IBCSG Trial IX. Proc Am Soc Clin Oncol 19: 281 (abstr).

Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc (B) 34: 187 – 220

Early Breast Cancer Trialists’ Collaborative Group (1998a) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930 – 942

Early Breast Cancer Trialists’ Collaborative Group (1998b) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451 – 1467

Falkson HC, Gray R, Wolberg WH, Gillchirst KW, Harris JE, Tormey DC, Falkson G (1989) Adjuvant therapy of post-menopausal women with breast cancer: an ECOG phase III study. J Clin Oncol 8: 599 – 607

Fetting JE, Gray R, Fairsingh DL, Smith TI, Magoulis KA, Citron ML, Groong M, Coates AS, Pignata S, Robert N, Hendriks IC, Osborne CK, Aboloff MD (1998) Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor- negative breast cancer: an Intergroup study. J Clin Oncol 16: 2382 – 2391

Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG, Bowman D, Wolmark N, Wickerham DL, Kardinal CG (1990) Two months of doxorubicin-cyclophosphamide with and without interval reintroduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8: 1483 – 1496

Fisher B, Anderson S, Wolmark N, Tan-Chiu E (2000) Chemotherapy with or without tamoxifen with ER negative breast cancer and negative node: Results from NSABP B23. Proc Am Soc Clin Oncol 19: 277 (abstr)

Goldhirsch A, Gelber RD, Castiglione M (1990) The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. Ann Oncol 1: 183 – 188

Goldhirsch A, Francis P, Castiglione-Gertsch M, Gelber RD, Coates AS (2000) Tamoxins as adjuvant for breast cancer [letter]. Lancet 356: 507 – 508

Harvey JM, Clark GM, Osborne CK, Alred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474 – 1481

Henderson C, Gelman RS, Harris JR, Canellos DC (1986) Duration of therapy in adjuvant chemotherapy trial. Natl Cancer Inst Monographs 1: 95

Henderson IC, Berry D, Demetri G, Cirrincione C, Goldstein L, Muss H, Norton L (1998) Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 17: 390a (abstr)

Hünlé C, Bernhard J, Coates AS, Castiglione-Gertsch M, Peterson HF, Gelber RD, Forbes JF, Rudenstam CM, Simioncini E, Critelli D, Goldhirsch A, Senn HJ (1996) Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. Lancet 347: 1279 – 1284

International Breast Cancer Study Group (1996) Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 14: 1885 – 1894

Jakesz R, Hausmaninger H, Samonigg H, Kubista E, Depisch D, Fridrik M, Stierer M, Gnant M, Steger G, Kolb R, Jatzko G, Hofbauer F, Reiner G, Luschin-Behnegreuth G (1999) Comparison of adjuvant therapy with tamoxifen and goserelin in premenopausal stage I and II hormone responsive breast cancer patients: Four-year results of Austrian Breast Cancer Study Group (ABC SG) Trial 5. Proc Am Soc Clin Oncol 18: 250 (abstr)

Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observation. J Am Stat Assoc 53: 457 – 481

We thank the patients, physicians, nurses, and data managers who participate in the International Breast Cancer Study Group (IBCSG) and the German Breast Cancer Study Group (GBSG) trials. We acknowledge the initial support provided for the IBCSG by the Ludwig Institute for Cancer Research, the Cancer League of Ticino, and the Swiss Cancer League. We further acknowledge the continuing support for IBCSG central coordination, data management, and statistics provided by the Swedish Cancer Society, The Cancer Council Australia, Australian New Zealand Breast Cancer Trials Group (NHRCC 880513 and 910420), Frontier Science and Technology Research Foundation, Swiss Group for Clinical Cancer Research, United States National Cancer Institute (CA-75362), and American-Italian Cancer Foundation (AICF 101-98 and 101-99). We acknowledge support for the Cape Town participants from the Cancer Association of South Africa. The GBSG support from the German Bundesministerium für Forschung und Technologie and from the German Research Foundation is gratefully acknowledged.
Duration of adjuvant chemotherapy for breast cancer

M Colleoni et al

Levine MN, Gent M, Hryniuk WM, Bramwell V, Abu-Zahra H, DePauw S, Arnold A, Findlay B, Levin L, Skillings J (1990) A randomized trial comparing 12 weeks with 36 weeks of adjuvant chemotherapy in stage II breast cancer. J Clin Oncol 8: 1217 – 1225

Ludwig Breast Cancer Study Group (1988) Combination adjuvant chemotherapy for node-positive breast cancer: inadequacy of a single perioperative cycle. N Engl J Med 319: 677 – 683

Ludwig Breast Cancer Study Group (1989) Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 320: 491 – 496

Maass H (2000) 3 versus 6 cycles of CMF in breast cancer patients with 1 to 9 positive nodes: results of the German Adjuvant Breast Cancer Group (GABG) III trial. Proc Am Soc Clin Oncol 19: 283 (abstr)

Pagani O, O'Neill A, Castiglione M, Gelber RD, Goldhirsch A, Rudenstam CM, Lindner J, Collins J, Crivellari D, Coates A, Cavalli F, Thurlimann B, Simoncini E, Fey M, Price K, Senn HJ (1998) Prognostic impact of amenorrhea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 34: 632 – 640

Roche HH, Kerbrat PP, Bonneterre J (2000) Complete hormonal blockade versus chemotherapy in premenopausal early stage breast cancer patients with positive hormone receptors and 1-3 node-positive tumors: results of the FASG 06 Trial. Proc Am Soc Clin Oncol 19: 279 (abstr)

Sauerbrei W, Bastert G, Bojar H, Beyerle C, Neumann RL, Schmoor C, Schumacher M (2000) Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients: an update based on 10 years’ follow-up. J Clin Oncol 18: 94 – 99

Schumacher M, Bastert G, Bojar H, Hubner K, Olschewski M, Sauerbrei W, Schmoor C, Beyerle C, Neumann RL, Rauschecker HF (1994) Randomized 2x2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. J Clin Oncol 12: 2086 – 2093

Scottish Cancer Trials Breast Group and ICRF Breast Unit (1993) Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 341: 1293 – 1298

Senn HJ, Jungi WF (1984) Swiss adjuvant trials with LMF (+BCG) in N— and N+ breast cancer patients. In Adjuvant therapy of cancer IV, Salmon SE (ed) pp 261 – 270 Orlando: Grune & Stratton